Company intelligence / Profile preview

TAP Pharmaceuticals

Lake Forest, Illinois, USAtappharma.ch ↗

Ownership: Private
Employees: ~320
Development stage: Commercial

Overview

TAP marketed two blockbuster drugs: lansoprazole (Prevacid), a proton-pump inhibitor for ulcers and acid reflux, and leuprorelin acetate depot injection (Lupron Depot), a leading prostate cancer drug. Both had worldwide sales exceeding $1 billion at peak[1][2].

Therapeutic areas: OncologyGastroenterology
Modalities: Small molecules (e.g., lansoprazole/Prevacid, leuprorelin/Lupron)
Industry: Pharma

Drug pipeline

2 assets

leuprorelin

Commercial

Indications: Prostate cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Joint venture partnership between Abbott Laboratories and Takeda Pharmaceutical Company from 1977 until dissolution in 2008[1][4].

Beyond the preview

Go deeper on TAP Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAP Pharmaceuticals.

Explore the full profile